Current portfolio

Artios Pharma

Next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy

  • Sector
    Healthcare
  • Country
    United Kingdom
  • Fund
    LSP 6
  • Entry
    2018
  • Web
Logo

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news
Preferred language
EQT logo© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180